Carolinas Wealth Consulting LLC Has $735,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Carolinas Wealth Consulting LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 122.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 5,083 shares of the company's stock after acquiring an additional 2,799 shares during the quarter. Carolinas Wealth Consulting LLC's holdings in Johnson & Johnson were worth $735,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $32,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth $36,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on JNJ shares. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

Shares of JNJ traded up $0.53 during midday trading on Thursday, reaching $152.96. The stock had a trading volume of 2,353,932 shares, compared to its average volume of 7,931,169. The firm's 50 day moving average price is $154.63 and its 200-day moving average price is $153.64. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market capitalization of $368.04 billion, a P/E ratio of 23.00, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.40%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.